Posted on 03/23/2020 10:44:15 AM PDT by mmichaels1970
A recent French peer review study by renowned infectious disease specialist Dr. Didier Raoult which was published in the International Journal of Antimicrobial Agents showed promising results in the treatment of COVID-19 with Hydroxychloroquine (HCQ).
The French study also showed a significant decrease in “viral shedding,” from patients treated with HCQ. The lower the shedding, the less likelihood that the virus can be communicated to other individuals.
As the medical profession evaluates different treatment options, public health officials should adopt early treatment measures with the existing tools at our disposal. HCQ is an inexpensive, safe drug that has been used in the treatment of malaria for seventy years.
With no vaccine or antiviral in place, HCQ is the lead candidate for early treatment against the COVID-19 virus. This was the conclusion of a recent medical paper written by Dr. Raymond Chang whose affiliations include the Institute of East-West Medicine in New York and the National Taiwan University Hospital in Taiwan.
HCQ has the ability to prevent the virus from entering the cell, as well as to prevent the virus from replicating. HCQ has the unique factor of being able to accumulate high concentrations in the lungs (specifically where it is needed). What is also appealing is the long duration (22 day half-life) of HCQ in the body. These factors make it promising for early treatment if ingested days before the virus is introduced.
Worldwide reaction to the virus has been one of containment through isolation and social distancing. The objective of early treatment is to decrease the time of isolation and social distancing. The longer the isolation the more devastating the effects on our lives. A nationwide program of early treatment with HCQ, along with concurrent isolation may reap exponential benefits. The existing record of HCQ, its promise of efficacy in the treatment of COVID-19 and low costs make the risk to benefit ratio well worth the effort.
Federal and State governments should immediately direct public policy towards increasing production, storage and establishing a distribution protocol and regimen for HCQ to ameliorate the spread of the COVID-19 virus. This was the conclusion reached by U.S. academic studies in response to French infectious disease specialist Dr. Raoult’s peer review study, saying HCQ has a strong potential as a prophylactic measure against the severity of COVID-19.
We the undersigned agree with New Jersey State Senator Joe Pennacchio that all levels of government should work together to ameliorate the COVID-19 pandemic by developing an early treatment to minimize the effects of the virus and reduce its communicability by decreasing viral shedding with the use of Hydroxychloroquine:
Anika Ackerman MD Urology
Joseph Addeo MD Oncology
Munir Ahmed MD Orthopedics
Niran Al-Agba DO Pediatrics
Frank Alario MD Internal Medicine
Sharon Carswell MD Family Medicine
Kimberly Corba MD Family Medicine
Doug Crane MD Internal Medicine
Madeline Danny DO Family Medicine
Philip DeFina PhD Neuroscientist Clinical Research US ARMY Intel
Anthony Dippolito MD MBA General & Colorectal Surgeon
John Eck MD Family Medicine
Josephine Feingold MD Emergency Medicine
Ken Fisher MD Family Medicine
Chris Garofalo MD Family Medicine
David Gee MD Family Medicine
Helen Gelhot MD General Surgery
Eric Gerwirtz MD Anesthesiology
Yvette Gozzo MD Pulmonology
Karladine Graves DO Family Medicine
Wayne Graves DO Emergency Medicine
Lee Gross MD Family Medicine
Avinash Gupta MD Cardiology
James Halper MD Neuropsychiatry & Internal Medicine
Scott Hardiman MD Otolaryngology
Kris Held MD Ophthalmology
Travis Hendricks MD Infectious Disease
Bindukumar Kansupada MD Cardiology
Cameron Knackstedt DO Family Medicine
Herbert Kunkle, Jr MD Orthopedic Surgery
Steve Kupferburg MD Otolaryngology
Lee Kurisko MD Radiology
Guru Lamba MD Hematology Oncology
Katarina Lindley DO Family Medicine
Jennifer Lorine DO Family Medicine/Neuromuscular Med OMT
Lee Merritt MD General Surgery, US Navy
Winslow Murdoch MD Family Medicine
Katherine Newland MD Emergency Medicine
Lisa Norberg DO Family Medicine
Fred Notarnicola MD Internal Medicine
Sheila Page DO Neuromuscular & Skeletal, AAPS President Texas
Kirit Kumar Pandya MD Urology
Prashant Parikh MD Primary Care
Philip Pattison MD Gastroenterology
Danae Powers MD Anesthesiology
Lee Pressler MD Urology
Samuel Putnam MD Interventional Radiology, US Army Flight Surgeon
Raj Raval MD Physiatrist, Interventional Pain
Luis Rodriguez Jr MD Interventional Radiology
Scott Roethle MD Anesthesiology
Sohayla Rostami DO General Surgery Resident
James Rowsey MD Ophthalmology
Christine Saba PharmD MD Pediatrics
Vinod Sanchetti MD Internal Medicine
Nikki Silverstein MD Ophthalmology
Marilyn Singleton MD JD Anesthesiology
Pat Smith MD Gynecology
Reed Smith MD Internal Medicine
Douglas Spiel MD Interventional Pain Radiology
Joel Strom DDS Dentist
James Thomas MD MBA Interventional Radiology, Naval Flight Surgeon
Teresa Thomas MD Internal Medicine
Josh Umber MD Family Medicine
Kip VanCamp DO Interventional Radiology
Craig Wax DO Family Medicine
Vicki Wooll MD MPH Family Medicine, Epidemiology
Marlene Wust-Smith MD Pediatrics
Yes.
22 day half life is long ....good in this case
Wouldn’t want it with say xanax..lol
Medical kit supplies. Dengue?
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.